A5023923057- Pulmonary Hypertension Research and Treatments
- Congenital Heart Disease Studies
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Neonatal Respiratory Health Research
- Vascular Anomalies and Treatments
- Nitric Oxide and Endothelin Effects
- Congenital Diaphragmatic Hernia Studies
- Liver Disease and Transplantation
- Neuroscience of respiration and sleep
- Cardiac Valve Diseases and Treatments
- Cardiac Arrhythmias and Treatments
- Transplantation: Methods and Outcomes
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Hemodynamic Monitoring and Therapy
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiovascular Conditions and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- High Altitude and Hypoxia
- Ultrasound in Clinical Applications
- Congenital heart defects research
- Cardiomyopathy and Myosin Studies
- Aortic Disease and Treatment Approaches
University of Colorado Denver
2016-2025
Children's Hospital Colorado
2016-2025
University of Colorado Anschutz Medical Campus
2013-2024
University of Cambridge
2021
University of Colorado Health
2003-2020
ORCID
2020
Baylor College of Medicine
2020
Columbia University Irving Medical Center
2018-2020
RELX Group (United States)
2019
Boston Children's Museum
2018
Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, older children contributes to significant morbidity mortality. However, current approaches caring for pediatric patients pulmonary have been limited by the lack of consensus guidelines from experts field. In a joint effort American Heart Association Thoracic Society, panel experienced clinicians clinician-scientists was assembled review literature make recommendations on...
Background— Pulmonary arterial hypertension (PAH) is a rare but important cause of morbidity and mortality in children. Methods Results— We analyzed data from 216 patients ≤18 years age at diagnosis who were enrolled the Registry to Evaluate Early Long-Term PAH Disease Management (REVEAL). Median enrollment was 7 15 years, respectively. The most frequent presenting symptom dyspnea (idiopathic/familial PAH, 53%; associated with congenital heart disease, 30%). Presyncope/syncope more...
Safe, effective therapy is needed for pediatric pulmonary arterial hypertension.Children (n=235; weight ≥8 kg) were randomized to low-, medium-, or high-dose sildenafil placebo orally 3 times daily 16 weeks in the Sildenafil Treatment-Naive Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension (STARTS-1) study. The primary comparison was percent change from baseline peak oxygen consumption (PV(O(2))) doses combined versus placebo. Exercise testing performed 115 children able...
In Brief BACKGROUND: Pulmonary arterial hypertension (PAH) can lead to significant cardiac dysfunction and is considered be associated with an increased risk of perioperative cardiovascular complications. METHODS: We reviewed the medical records children PAH who underwent anesthesia or sedation for noncardiac surgical procedures catheterizations from 1999 2004. The incidence, type, factors complications occurring intraoperatively through 48 h postoperatively were examined. RESULTS: Two...
OBJECTIVE. The goal was to determine the clinical utility of Doppler echocardiography in predicting presence and severity pulmonary hypertension patients with chronic lung disease who subsequently underwent cardiac catheterization. METHODS. A retrospective review data for all <2 years age a diagnosis bronchopulmonary dysplasia, congenital diaphragmatic hernia, or hypoplasia catheterization evaluation performed. accuracy diagnosing hypertension, on basis estimated systolic artery...
Current classifications of pulmonary hypertension have contributed a great deal to our understanding vascular disease, facilitated drug trials, and improved congenital heart disease in adult survivors. However, these are not applicable readily pediatric disease. The classification system that we propose is based firmly clinical practice. specific aims this new improve diagnostic strategies, promote appropriate investigation, pathogenesis, physiology epidemiology, guide the development human...
Background— The double-blind, placebo-controlled Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension (STARTS-1) study assessed sildenafil pediatric patients with pulmonary arterial hypertension; improved hemodynamics and exercise capacity occurred medium- high-dose groups. STARTS-2 was the extension study. Methods Results— In STARTS-1, 234 children ≥8 kg were randomly assigned low-, medium-, or placebo orally thrice daily; within-group dose...
Background Current mortality data for pulmonary arterial hypertension (PAH) in the United States are based on registries that enrolled patients prior to 2010. We sought determine PAH modern era using PHAR (Pulmonary Hypertension Association Registry). Methods and Results identified all adult with between September 2015 2020 (N=935). used Kaplan‐Meier survival analysis Cox proportional hazards models assess at 1, 2, 3 years. Patients were stratified disease severity by validated risk scores....
RhoA GTPase mediates a variety of cellular responses, including activation the contractile apparatus, growth, and gene expression. Acute hypoxia activates and, in turn, its downstream effector, Rho-kinase, previous studies rats have suggested role for Rho/Rho-kinase signaling both acute chronically hypoxic pulmonary vasoconstriction. We therefore hypothesized that circulation mice contributes to vasoconstriction chronic hypoxia-induced hypertension vascular remodeling. In isolated, salt...
Pulmonary hypertension contributes significantly to morbidity and mortality in bronchopulmonary dysplasia (BPD), but little is known about the relative contribution of arterial tone, structural remodeling, vessel density pulmonary hypertension, especially older patients. To determine role high vascular tone we studied acute effects oxygen tension, inhaled nitric oxide (iNO), calcium channel blockers (CCB) 10 patients with BPD who underwent cardiac catheterization for evaluation hypertension....
Pulmonary arterial hypertension (PAH) is a rare disease characterized by distinctive changes in pulmonary arterioles that lead to progressive pressures, right-sided heart failure, and high mortality rate. Up 30% of adult 75% pediatric PAH cases are associated with congenital (PAH-CHD), the underlying etiology largely unknown. There no known major risk genes for PAH-CHD.